anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To assess the impact of clinical neonatal seizures on outcome characteristics of preterm and term newborns with neonatal encephalopathy (NE).
METHODS: We designed a prospective comparative study with 53 babies (preterm neonates: 26 and term neonates: 27) with NE: group 1 (preterm neonates with seizures, n = 13), group 2 (preterm neonates without seizures, n = 13), group 3 (term neonates with seizures, n = 13) and group 4 (term neonates without seizures, n = 14). The functional outcome characteristics of the survivors were assessed by the Ankara Developmental Screening Inventory (ADSI) and the Guide for Monitoring Child Development (GMCD) at 12 months of age.
RESULTS: Clinically defined acute symptomatic seizures were diagnosed with prompt conventional EEG / amplitude-integrated EEG in preterm (92.3%) and term neonates (81.4%) with etiology-specific diagnoses of NE. There were no differences between the study groups regarding seizure semiology and EEG characteristics. A primary adverse outcome was defined in 22 (41.5%) of the cohort. However, only 15.3% of infants had an unfavorable functional outcome with ADSI at 12 months. Among the survivors, there was no significant difference between the study groups regarding ADSI scores. The GMDC test revealed normal development in 50% of survivors with seizures in the preterm group and 83% in the term group.
CONCLUSION: There was no significant difference between the characteristics of functional outcomes at 12 months in preterm and term neonates with NE for clinical seizures.
Participants received avacincaptad pegol (ACP) 2 milligram (mg)/eye via intravitreal (IVT) injections monthly through Month 11 (Year 1). At month 12, participants were re-randomized to receive ACP 2 mg/eye via IVT injections monthly from month12 through month 23 (Year 2).
Autoimmune disorders place a substantial burden on the healthcare system all over the world affecting almost 3% to 8% of the population. Immune thrombocytopenic purpura (ITP), also known as idiopathic thrombocytopenic purpura, is a blood disorder in which the body immune system destroys platelets, leading to low platelet counts in the blood (peripheral blood platelet count < 150 × 109/L). Although the pathophysiology of ITP is not fully understood, it is believed to result from a complex interplay between hereditary and environmental variables. Certain factors, such as a low platelet count, history of bleeding, and certain comorbidities can increase the risk of severe bleeding in patients with ITP. Corticosteroids, intravenous immunoglobulin (IVIG), immunosuppressants, rituximab, and thrombopoietin receptor agonists (TPO-RAs) are some of the advanced treatments for ITP. Although these therapies may be successful, they also carry the risk of negative effects. Recently, significant advancements have been made in the understanding and treatment of ITP. There is still much to learn about the disease, and new, more effective treatments are needed. This comprehensive review offers a comprehensive assessment of recent advancements in ITP management, with a focus on active research projects, novel therapeutic targets, new treatment modalities, and areas of uncertainty and unmet needs. According to research, it is crucial to develop individualized treatment plans for ITP patients based on their age, platelet count, risk of bleeding, and comorbidities. The article also looks at how future developments in gene editing, bispecific antibody therapies, and cellular therapy may completely change the treatment of ITP.
FIELD: organic chemistry, steroids, vitamins. SUBSTANCE: invention relates to analogs of vitamin D of the formula (I)   where R means the group:   where q = 0, 1; n = 2-4; m = 0; Y 1  and Y 2  mean independently hydrogen or halogen atom; R 1  and R 2  mean independently hydrogen atom, lower alkyl optionally substituted with halogen atoms or azido-group; X means hydrogen atom of hydroxy-group being the present hydroxy-groups are protected. Invention describes also the pharmaceutical composition showing the inhibitory activity with respect to proliferation of tumor cells based on compounds (I). Compounds show anti-inflammatory and immunomodulating effects and strong activity stimulating differentiation and inhibiting unfavorable proliferation of some cells. EFFECT: improved method of synthesis, valuable medicinal properties. 8 cl, 4 tbl, 2 dwg, 11 ex
Overall 60 treatments (5 days per weeks for 12 weeks). 90 minutes every session. Pressure of 2 atm. Inhalation of 100% oxygen.
<P>PROBLEM TO BE SOLVED: To obtain an antioxidative immunopotentiating composition that is largely available because it can be easily produced and has excellent antioxidative immunopotentiating action, to provide a functional food prepared by processing the composition and a method for increasing the antioxidative immunopotentiating action.  <P>SOLUTION: The antioxidative immunopotentiating composition contains 100 pts.wt. of a component of Hericium erinaceum and less that 100 pts.wt. of a component of Phellinus linteus but is free from superoxide dismutase. In the method for increasing the antioxidative immunopotentiating action by using the above components, the amount of the latter component is made lower than 100 pts.wt. per 100 pts.wt. of the former component characteristically.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PURPOSE:To obtain a bathing agent composition having excellent effect to keep the moisture and prevent the dryness of the skin, free from tacky feeling of the skin after bathing and giving moist skin by using an interkeratocytic lipid or a substance having similar structure and a silicone as active components. CONSTITUTION:The objective composition contains (A) 0.1-60wt.% of an interkeratocytic lipid (e.g. ceramide or cholesteryl ester) or a substance having similar structure and (B) 1-50wt.% of a silicone oil (e.g. methylphenylpolysiloxane) based on the total composition as active components. The active components are compounded with oily component, dispersing agent or emulsifying agent for the oily component and conventional component for ordinary bathing agent and formed in the form of powder, granule, tablet, liquid, etc. The agent is thrown into bath water before bathing. The amount of the agent is selected to give the bath water containing 0.1-500ppm (preferably 0.2-400ppm) each of the components A and B.
Cardioselective β-blockade is generally well tolerated in practice and contraindications to this therapy are uncommon. β-blockers are a diverse therapeutic class, and their individual tolerability profiles are influenced strongly by their pharmacodynamic effects across different adrenergic receptors. Bisoprolol, probably the β-blocker with the highest selectivity for blockade of β1- vs. β2-adrenoceptors, does not block β2-adrenoceptors to an appreciable extent at doses in therapeutic use. Side-effects often attributed to β-blockers, such as erectile dysfunction and adverse metabolic effects are uncommon with bisoprolol and other β-blockers used at doses which only block β1-adrenoceptors. Cautious use of a cardioselective β-blocker is not contraindicated in people with chronic obstructive pulmonary disease or asthma and the outcomes benefits of β-blockers in patients with coronary heart disease or heart failure are also apparent in patients with concurrent COPD. Starting with a low dose and titrating upwards carefully is important for optimising the tolerability of a β-blocker. Most people with hypertension will receive combination antihypertensive therapy in practice, and the low-dose combination therapy approach provides a useful strategy for optimising the efficacy and tolerability of a regimen that includes a β-blocker, compared with up-titrating an existing monotherapy.
The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson \& Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate.
Patients in Cohort B, Arm IV undergo ctDNA surveillance consisting of collection of tissue and blood during screening and collection of blood only on study and during follow up. Patients who convert to ctDNA(+) during surveillance then receive nivolumab IV over 30 minutes and relatlimab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI scans throughout the trial.
Participants receive usual care and wear actigraph activity monitor and complete a sleep diary for 7 days. Participants have the option to attend Tibetan yoga sessions upon completion of 12-month follow-up.
The invention provides a tree peony essential oil and a preparation method thereof. Firstly natural tree peony petal with pleasant flavour is pickled with sodium chloride, and then steam distillation is carried out to obtain an extract, thus solving the problem that fresh tree peony petals are difficult to retain freshness and store. Tree peony seeds are selected and are subjected to cold rolling to obtain crude oil, column chromatographic separation is carried out, the separated solution is collected, a molecular interception method is adopted for interception, and the intercepted solution is obtained. Confecting is carried out according to certain proportion, thus the blended skin oil has light natural tree peony oil flavour. The tree peony essential oil can relieve the stressful feeling and has the effects of restoring consciousness, improving eyesight, enhancing the intelligence, improving memory, resisting bacteria and viruses, repelling mosquitoes and covering up unpleasant odour. By applying the essential oil, the menstrual periods of the female can be conditioned, and sleeping can be improved; skin toxin can be eliminated, and dry skin and pore shrinkage can be improved; oxygen radical can be effectively eliminated, chromogenesis on skin can be inhibited, wrinkles can be removed, and skin stain and female stretch marks can be reduced; and blood micro circulation can be improved, thus the skin is glossy and elastic. Besides, the essential oil has the unique effects of moisturizing, beautifying, protecting the skin and deferring senility.
INTRODUCTION AND OBJECTIVES: The HepHIV 2023 Conference, held in Madrid in November 2023, highlighted how Europe is not on track to meet the United Nations (UN) sustainable development goals and Joint UN Programme on HIV/AIDS (UNAIDS) targets. This article presents the outcomes of the conference, which focus on ways to improve testing and linkage to care for HIV, viral hepatitis, and other sexually transmitted infections. HIV-related stigma and discrimination, a major barrier to progress, was a key concept of the conference and on the agenda of the Spanish Presidency of the European Union.
METHODS: The HepHIV 2023 organizing committee, alongside the Spanish Ministry of Health, oversaw the conference organization and prepared the scientific programme based on abstract rankings. Key outcomes are derived from conference presentations and discussions.
RESULTS: Conference presentations covered the obstacles that HIV-related stigma and discrimination continue to pose to access to services, models for data collection to better monitor progress in the future, and examples of legislative action that can be taken at national levels. Diversification of testing approaches was also highlighted, to reach key populations, (e.g. migrant populations), to increase testing offered in healthcare settings (e.g. emergency departments), and to account for different stages of epidemics across the region.
CONCLUSION: With a strong call for intensified action to address the impact of HIV-related stigma and discrimination on testing uptake, the conference concluded that strengthened collaboration is required between governments and implementers around testing and linkage to care. There is also an ongoing need to ensure sustainable political commitment and appropriate resource allocation to address gaps and inequalities in access for key populations and to focus on the implementation of integrated responses to HIV, viral hepatitis, and sexually transmitted infections.
The present invention relates generally to a method of diagnosing and/or monitoring the development or progress of chronic fatigue syndrome. More particularly, the present invention relates to a method of diagnosing and/or monitoring the development or progress of chronic fatigue syndrome by analysis of activin ß? expression levels in a subject mammal or in a biological sample derived from said mammal. This may be achieved by screening for activin ßB in either monomeric form or in dimeric form. Still further, the ratio of the dimeric form of activin ß? relative to follistatin and activin A levels also provides a useful diagnostic indicator. In a related aspect there is provided a method for the treatment of chronic fatigue syndrome by dovvnregulating the functional level of activin B.
It is recommended to routinely screen for chromosomal karyotype, FLT3/ITD, FLT3/TKD and IDH1 mutations before enrollment.According to the patient's condition and physical condition, evaluate whether there is a suitable new drug clinical trial to enroll, if there is, enter the Arm 7 (new drug clinical trial); If not, enter other arm of the clinical study.According to the results of gene mutation, patients with target gene mutations should enter the corresponding study cohort (Arm1, Arm2), and select the regimen of specific targeted drug composition. For patients without a target mutation, patients eligible for intensive chemotherapy who had not received Venetoclax in the last 3 months were randomized to the Daunorubicin/idarbicin/mitoxantrone combination cytarabine + Venetoclax(DAV) (Arm3) and the Hyperhardinine combination cytarabine + Venetoclax cohort (HAV) (Arm4). Patients who were intolerant to intense chemotherapy were enrolled in the Venetoclax combined with Azacitidine cohort (Arm5). For patients who have failed treatment with Venetoclax within the last 3 months, the Venetoclax-based regimen is not recommended again and the physician is advised to conduct an exploratory trial (Arm6). After CR form induction therapy, allogeneic hematopoietic stem cell transplantation should be selected as far as possible according to the patient's wishes. For patients who are unable or unwilling to undergo allogeneic hematopoietic stem cell transplantation, physicians may choose post-remission consolidation therapy based on experience.
This study was conducted to evaluate the effects of Allium hookeri (AH) leaves cultivated with different light-emitting diode (LED) intensities (L: low, 100 μmol/m2/s; M: medium, 150 μmol/m2/s; H: high, 200 μmol/m2/s). Alliin concentration increased as light intensity increased in AH and showed the highest level at LED-H condition. The anti-obesity and immunomodulatory properties of AH were evaluated in a cyclophosphamide (CPA)-induced immunosuppressed obese animal model. C57BL/6 J mice were randomly divided into control (CON), high-fat diet (HFD) control (CON-H), negative control (NC), positive control (PC, β-glucan, 50 mg/kg body weight (BW)), AH L, M, and H groups. The three kinds of AH extracts were orally administered to the mice at 300 mg/kg BW for 2 weeks. Except for CON and CON-H, all the other groups were intraperitoneally treated with CPA. Epididymal and abdominal fat weight decreased as LED intensity increased while spleen weight increased in the AH groups. Serum glucose decreased as LED intensity increased in the AH groups and H group showed the lowest level. Triglycerides, total, and LDL-cholesterol levels decreased while HDL-cholesterol level increased in the AH groups compared to the NC group. Moreover, AH effectively reduced serum ALT and AST levels and increased the total white blood cell count, particularly elevating lymphocyte and monocyte levels. Furthermore, NK cell activity was higher in the AH groups. These findings suggest that AH cultivated at optimal LED intensity could be used as a novel biomedicine and in pharmacotherapy to treat related diseases to improve public health without any toxicity.
The intervention group parents will be taught the FASTER assessment tool. Intervention group parents will each be asked to monitor their own hospitalized child hourly using the FASTER assessment tool, and put up color-coded flags indicating severity of illness to the healthcare team. Parents will record the frequency of healthcare provider assessments of their child over the 24 hour intervention period.
BACKGROUND West Nile virus (WNV) is a vector-borne flavivirus that is typically transmitted by Aedes and Anopheles mosquitos. WNV infection typically presents with symptoms consistent with viral meningitis, which include fever, headache, and meningeal signs. WNV infections are typically self-resolving, with symptoms lasting 3-10 days. Although uncommon, patients with WNV infection can be afflicted with hyponatremia, although the etiology is unclear. Because of encephalitis, neuroinflammation may be involved in the deterioration of adrenal signaling, leading to salt wasting. CASE REPORT We present the case of a 75-year-old man who presented with headache, neck pain, photophobia, and viral illness symptoms. He was found to be profoundly hyponatremic, concerning for SIADH. He had a sodium drop to 117 mmol/L, leading to further lethargy and confusion. He received 3% saline, fluid restriction, and salt tablets, and more common causes of SIADH were ruled out. MRI revealed the absence of the posterior pituitary bright spot. He was subsequently found to have positive WNV titers and improved with continued supportive treatment. CONCLUSIONS WNV presents a unique challenge to providers due to its difficult diagnosis and association with hyponatremia. There is no clear role for specific medical treatment such as corticosteroids vs IV immunoglobulins. Supportive care is recommended for those testing positive for WNV. Clinicians should consider the possibility of viral infections, such as WNV, in patients living in endemic areas who present with unexplained hyponatremia, cognitive symptoms, and relevant history.
The invention relates to a traditional Chinese medicine composition for treating liver cirrhosis and an acupuncture point combined application. The traditional Chinese medicine composition is characterized by being prepared from the following traditional Chinese medicinal raw materials by weight: 4-10g of yeast, 4-10g of astragalus membranaceus, 2-4g of endothelium corneum gigeriae galli, 3-6g of pericarpium citri reticulatae, 3-6g of medicated leaven, 3-6g of angelica sinensis, 5-10g of rhizoma atractylodis, 5-10g of human placenta and the like. After combining the traditional Chinese medicinal raw materials, the traditional Chinese medicine composition has the functions of clearing away heat and toxic materials, resisting viruses, clearing heat, adjusting immunity, promoting blood circulation to remove blood stasis, nourishing liver and diminishing swelling, regulating and protecting liver, clearing heat and expelling damp and the like. In compatibility, acupoints such as tanshu, taichong, yanglingquan, ganshu, zhiyang, zusanli, pishu, qimen, tianshu and the like are combined with acupuncture stimulation to form a physical stimulation acupuncture point therapy, and the traditional Chinese medicine composition and the therapy are combined and matched in treatment to achieve the optimal effect of treating liver cirrhosis. The therapy is coordinated with the effect to treat both symptoms and root causes, so that the immune function of the body is improved and protected. The curative effect is remarkable, the method is simple, the treatment course is short, the medication is simple and feasible, the curative effect is fast, the effect is good and the cost is low.
Carcinogenesis

Long-term studies in animals to determine the carcinogenic potential of moxifloxacin have not been performed. However, in an accelerated study with initiators and promoters, moxifloxacin was not carcinogenic in rats following up to 38 weeks of oral dosing at 500 mg/kg/day (3224 times the highest recommended total daily human ophthalmic dose for a 60 kg person, based on body surface area). 

Mutagenesis

Moxifloxacin was not mutagenic in four bacterial strains used in the Ames Salmonella reversion assay. As with other quinolones, the positive response observed with moxifloxacin in strain TA 102 using the same assay may be due to the inhibition of DNA gyrase. Moxifloxacin was not mutagenic in the CHO/HGPRT mammalian cell gene mutation assay. An equivocal result was obtained in the same assay when V79 cells were used. Moxifloxacin was clastogenic in the V79 chromosome aberration assay, but it did not induce unscheduled DNA synthesis in cultured rat hepatocytes. There was no evidence of genotoxicity in vivo in a micronucleus test or a dominant lethal test in mice. 

Impairment of Fertility

Moxifloxacin had no effect on fertility in male and female rats at oral doses as high as 500 mg/kg/day, approximately 3,224 times the highest recommended total daily human ophthalmic dose, based on body surface area. At 500 mg/kg/day orally there were slight effects on sperm morphology (head-tail separation) in male rats and on the estrous cycle in female rats.
Despite decades of research, we still do not understand how spontaneous human seizures start and spread - especially at the level of neuronal microcircuits. In this study, we used laminar arrays of micro-electrodes to simultaneously record the local field potentials and multi-unit neural activities across the six layers of the neocortex during focal seizures in humans. We found that, within the ictal onset zone, the discharges generated during a seizure consisted of current sinks and sources only within the infra-granular and granular layers. Outside of the seizure onset zone, ictal discharges reflected current flow in the supra-granular layers. Interestingly, these patterns of current flow evolved during the course of the seizure - especially outside the seizure onset zone where superficial sinks and sources extended into the deeper layers. Based on these observations, a framework describing cortical-cortical dynamics of seizures is proposed with implications for seizure localization, surgical targeting, and neuromodulation techniques to block the generation and propagation of seizures.
A care management system for improving the care of a client who is supported by a caregiver is described. The caregiver may participate in regular activities with the client and record these activities in the care management system. The care management system may present the caregiver with questions on a regular basis. Information may also be input into the system by a care management team made up of professionals responsible for the client's overall care. A risk analyzer may determine the client's risk for different risk conditions, and may calculate domain-specific and overall risk scores for the client. Furthermore, the risk analyzer may make recommendations for actions to be taken by the client, the caregiver, or the care management team in order to improve the client's care. The information in the care management system may be used by the care management team to direct aspects of the client's care.